Peptide Stacking Protocols: What the Evidence Shows

Why people combine peptides

Stacking means using two or more peptides over the same period. The case for it is pharmacological. If two compounds push toward the same goal through different receptors, the combined effect can be larger than what either gives alone, at any dose. Endocrinologists call that synergy, and it has a strict meaning: the combination has to beat the sum of the two compounds given separately, not just beat one of them.

That standard matters because most stacks discussed on forums or sold as pre-mixed blends have never been tested together. Among the peptides on this page, only one pairing has human data showing synergy: a growth hormone-releasing hormone (GHRH) analog combined with a growth hormone-releasing peptide (GHRP). Everything else rests on mechanism and on data for each compound alone, mostly from rodents. For how the individual compounds compare, see our comparison of different peptides.

GHRH plus GHRP: the stack with human data

The pituitary releases growth hormone (GH) in pulses and responds to two separate stimulating signals. GHRH acts on its own receptor on the GH-producing cells. GHRPs such as GHRP-6, GHRP-2, hexarelin and ipamorelin act on a different receptor, later found to be the receptor for the gut hormone ghrelin. GHRPs are also thought to blunt somatostatin, the hormone that holds GH release back. Because the two signals travel different routes, giving both at once can release more GH than a larger dose of either. The growth hormone pathway explains these signals in more detail.

What the 1990 and 1994 studies showed

The founding study came from Cyril Bowers and colleagues in 1990. They gave 18 healthy men intravenous GHRP-6 at 0.1, 0.3 or 1.0 mcg/kg, GHRH at 1.0 mcg/kg, or the two together. The low, submaximal doses of GHRP-6 combined with GHRH released GH synergistically, which the authors read as a sign that the two peptides work independently. Prolactin and cortisol roughly doubled at the highest GHRP-6 dose but not at the lower ones.

In 1994, Arvat and colleagues in Turin tested hexarelin with GHRH in 13 young and 16 elderly men, using single IV doses of 2 mcg/kg of each. In the young men, the GH response (measured as area under the curve) was about 4,850 for hexarelin alone, 1,455 for GHRH alone and 7,725 for the two together, which is more than the two separate responses added up. The older men responded less to everything, but the combination still beat either peptide by itself.

Both were small, single-dose IV studies in healthy men that tracked GH in the blood for a couple of hours. They show the pairing raises GH more. They don't show that it changes muscle or fat, and no trial has tested body-composition outcomes for any GHRH plus GHRP combination. As of October 2026, we found no controlled human trial of the pairing most users actually run, Mod GRF 1-29 (CJC-1295 without DAC) with ipamorelin.

Combinations users report

None of the doses below comes from a trial of the combination.

Users often pick ipamorelin because it's said to raise cortisol and prolactin less than GHRP-2 or GHRP-6. That reputation comes mostly from early laboratory work, and human comparisons are scarce. The site rates ipamorelin's evidence as moderate: its one Phase 2 trial, in 117 adults recovering from abdominal surgery, missed its primary endpoint, and development stopped. GHRP-6 users commonly report intense hunger soon after injection.

The "GH bleed" claim

Many stack guides say CJC-1295 with DAC creates a steady "GH bleed" in place of normal pulses. A 2006 study by Ionescu and Frohman measured this directly. Healthy men aged 20-40 received one injection of 60 or 90 mcg/kg, with blood drawn every 20 minutes overnight before the dose and a week after it. The frequency and size of GH pulses didn't change. What rose was the trough between pulses, about 7.5-fold, which lifted mean GH by 46% and IGF-1 by 45%. So the pulses stay; the floor under them rises. The pulse-versus-bleed debate is covered in how half-life shapes dosing schedules.

BPC-157 plus TB-500: the "repair stack"

Vendors and forum guides often market this pairing as synergistic for tendon and joint injuries, on the reasoning that the two act on different parts of healing. In rodent studies, BPC-157 has been linked to new blood vessel growth (angiogenesis) and faster tendon and ligament repair; one 2010 rat study, for example, reported better ligament healing. TB-500 is usually described through thymosin beta-4, a 43-amino-acid protein that binds actin and is involved in cell migration.

TB-500 isn't synthetic thymosin beta-4, though. A 2012 doping-lab analysis identified the active ingredient in products sold as TB-500 as Ac-LKKTETQ, an acetylated 7-residue fragment (residues 17-23) of the full protein. Human trials of full thymosin beta-4 don't carry over to that fragment, and as of October 2026 FDA says it has found no human exposure data for it. The site rates TB-500's evidence as preliminary and BPC-157's as emerging: BPC-157 has consistent rodent data but only three small, uncontrolled human pilots.

No human trial has tested the combination. The closest thing is a 2021 retrospective report by Lee and Padgett, summarized in a 2025 review: 16 patients who had received knee injections of BPC-157 alone or BPC-157 with thymosin beta-4 were contacted 6-12 months later, and 14 reported significant pain relief. There was no control group, and that figure pools both groups, so it can't show whether adding the second peptide changed anything.

Reported doses come from users and vendors, not trials. Users commonly describe 250-500 mcg of BPC-157 a day by subcutaneous injection. Vendor guidance for TB-500 describes 2-2.5 mg twice weekly for 4-6 weeks, then monthly doses, while forum users describe 2-5 mg twice weekly; no human dose of the fragment has been tested. In user reports, some people describe clear improvement within weeks and others notice nothing, and some report fatigue or low mood early on. Natural healing and variable gray-market product quality may explain part of that gap.

As of October 2026, the first registered trial of BPC-157 for a musculoskeletal injury, a University of Arkansas Phase 1 study after rotator cuff repair (NCT07803250, about 30 participants estimated), isn't yet recruiting and is set to start in January 2027. It tests BPC-157 alone, so it won't answer the combination question.

Is there a fat-loss stack?

We found no evidence for one. The pairing often proposed, HGH Fragment 176-191 with AOD-9604, is two versions of nearly the same molecule: FDA's 2024 review describes AOD-9604 as the 177-191 fragment of human growth hormone with an extra tyrosine.

The human data on AOD-9604 are also negative. In the OPTIONS trial (536 adults with obesity enrolled, 502 randomized), oral doses of 0.25, 0.5 or 1 mg a day, alongside diet and exercise, produced weight loss too small to reach statistical significance against placebo at 12 or 24 weeks, and development for obesity was terminated. Users commonly describe 300 mcg by subcutaneous injection once daily, but no human trial has tested injected AOD-9604.

The peptides with strong fat-loss evidence are approved prescription medicines, such as semaglutide (Wegovy) and tirzepatide (Zepbound, approved by FDA for chronic weight management in November 2023). Their trials tested each drug with diet and exercise, not as part of a stack. Research-use vials sold under the same names aren't the approved products and don't carry the same quality oversight.

Why more compounds make results unreadable

Starting five or six peptides at once makes it impossible to tell what did what. An improvement can't be credited to any one compound, and side effects overlap: water retention and tingling hands are reported with GHRPs and GHRH analogs alike, and early fatigue is reported with BPC-157 and TB-500. Pre-mixed blend vials add another layer, because the amount of each peptide depends on the vendor's label. Some experienced users describe adding one compound at a time and holding everything else steady for several weeks, which at least lets a change be traced to a single variable. Many also cycle GH secretagogues on and off; peptide cycling in bodybuilding covers that.

What we still don't know

The GHRH plus GHRP synergy is real for acute GH release, but nobody has shown that it produces more muscle or less fat than one peptide over months. Nobody has tested BPC-157 with TB-500 against either alone in people, and the TB-500 fragment has no human safety data of its own. Long-term effects of running several GH-raising compounds together are also unstudied; what's known about long-term effects summarizes the single-compound data.